We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim announced Thursday that it has acquired all shares of ViraTherapeutics for a total of 210 million euros ($244 million), with the price based on an option and share purchase agreement signed between the companies in 2016.